Stock Analysis
Cyxone Second Quarter 2024 Earnings: kr0.02 loss per share (vs kr0.045 loss in 2Q 2023)
Cyxone (STO:CYXO) Second Quarter 2024 Results
Key Financial Results
- Net loss: kr4.75m (loss widened by 12% from 2Q 2023).
- kr0.02 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cyxone Earnings Insights
Looking ahead, revenue is expected to decline by 122% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Sweden are expected to grow by 18%.
Performance of the Swedish Biotechs industry.
The company's shares are up 11% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Cyxone has 6 warning signs (and 5 which shouldn't be ignored) we think you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:CYXO
Cyxone
A clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases.